EGFR and non-small cell lung carcinoma: Two phase III trials assessed the combination of figitumumab with cytotoxic chemotherapy (paclitaxel and carboplatin) and EGFR-TKI (erlotinib) in patients with advanced NSCLC were closed early with disappointing consequences (66, 67).